FIELD: organic chemistry, chemical technology.
SUBSTANCE: invention describes an improved method for synthesis of 17β-substituted 4-azaandrost-1-en-3-one of the general formula (I): wherein R means -OH, (C1-C4)-alkyl, (C1-C4)-alkenyl, phenyl, benzyl and others, or their pharmaceutically acceptable salts. Method involves insertion protective groups into 3-keto-4-aza (lactam) form of compound of the general formula (II): wherein R has indicated values to form compound of the general formula (III): wherein R3 means trialkylsilyl, or in common with R4 residue -C(O)-C(O)- or -C(O)-Y-C(O)- wherein R4 means tert.-butyloxycarbonyl preferably; Y means -(CH2)n wherein n = 1-4, or ortho-phenylene. Then a synthesized compound is converted in the presence of a dehydrogenation catalyst of in the presence of benzoquinone, allylmethylcarbonate, allylethylcarbonate and/or allylpropylcarbonate, and ▵1-double bond is introduced in 1,2-position followed by removal of protective groups and, if necessary, (when R means -OH) conversion to salts. Method provides the high yield and purity degree of synthesized compounds.
EFFECT: improved method of synthesis.
21 cl, 9 ex
Title |
Year |
Author |
Number |
METHOD OF TREATMENT OF PATIENTS WITH PROSTATE BENIGNITY HYPERPLASIA, PHARMACEUTICAL PREPARATION CONTAINING INHIBITOR OF 5-ALPHA-REDUCTASE |
1992 |
- Glenn Dzh.Gomlej
- Ehlizabet Stoner
|
RU2125879C1 |
FLUORINATED DERIVATIVES OF 17β-SUBSTITUTED-4-AZA--5α-ANDROSTANE- -3-ONE, PHARMACEUTICAL COMPOSITION |
1993 |
- Akille Pantseri
- Marchella Nesi
- Ehnriko Di Salle
|
RU2125061C1 |
INHIBITORS OF TESTOSTERONE 5α-REDUCTASE, PHARMACEUTICAL COMPOSITION, METHOD OF INHIBITION OF TESTOSTERONE 5α-REDUCTASE ACTIVITY |
1993 |
- Fernand Labri
- Iv Meran
- Shankar M.Singkh
|
RU2141967C1 |
ANTIANDROGENIC COMPOUNDS, PRECURSOR OF ANTIANDROGENIC COMPOUND, PHARMACEUTICAL COMPOSITIONS |
1993 |
- Fernand Labri
- Iv Merand
- Shankar M.Singkh
|
RU2141966C1 |
ANDROSTEN(ANE) (ONE) DERIVATIVES OR PHARMACEUTICALLY ACCEPTABLE SOLVATE THEREOF, METHODS OF PREPARATION THEREOF, AND METHOD OF MEDICAL TREATMENT |
1994 |
- Behchelor Kennet Uil'Jam
- Fraj Stiven Vernon
|
RU2144037C1 |
3-CYANOANDROSTA-3,5-DIENE-17BETA-CARBOXYLIC ACID AS INTERMEDIATE PRODUCT, AND METHOD OF PREPARING COMPOUNDS |
1993 |
- Koiti Kodzima
- Khitosi Kurata
- Koki Isibasi
- Takakazu Khamada
- Khirojossi Khorikosi
|
RU2114861C1 |
POLYCYCLIC COMPOUND ACTING AS KINASE INHIBITOR |
2021 |
- Zhang, Hancheng
- Cheng, Xin
- Jia, Wei
- Cai, Congcong
|
RU2826488C1 |
17$$$-SUBSTITUTED 3-CARBOXYSTEROIDS, METHOD OF THEIR SYNTHESIS, PHARMACEUTICAL COMPOSITION |
1992 |
- Akille Pantseri[It]
- Marchella Nesi[It]
- Ehnriko Di Salle[It]
|
RU2104283C1 |
DOUBLE ANTITHROMBOTIC INHIBITORS CONTAINING BIOTIN RESIDUE |
2005 |
- De Kort Martin
- Van Bukkel Konstant Adrian Anton
|
RU2403259C2 |
DERIVATIVES OF PYRROLO[2,3-D]PYRIMIDINES, PHARMACEUTICAL COMPOSITION, PYRROLO[2,3-D]PYRIMIDINES, DERIVATIVES OF PYRROLE |
1993 |
|
RU2124015C1 |